Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis‐related fibrosis: Multicenter study
暂无分享,去创建一个
T. Okanoue | A. Morishita | H. Toyoda | S. Aishima | K. Tomita | E. Miyoshi | H. Fujii | M. Yoneda | Yuya Seko | K. Yamaguchi | Y. Itoh | H. Hayashi | S. Oeda | T. Ikegami | Y. Yoshida | Y. Kamada | Y. Sumida | T. Shima | M. Kawanaka | K. Notsumata | K. Kawata | Michihiro Iwaki | Hirokazu Takahashi | Atsushi Nakajima | T. Arai | H. Fukushima | A. Nakajima
[1] T. Kawaguchi,et al. Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-Based Cohort Study. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[2] J. Gornbein,et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. , 2021, Journal of hepatology.
[3] K. Chayama,et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020 , 2021, Journal of Gastroenterology.
[4] W. Rosenberg,et al. Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis , 2021, Journal of gastroenterology and hepatology.
[5] C. Sirlin,et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis , 2020, Gut.
[6] N. Chalasani,et al. A Novel Blood-based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[7] P. Bossuyt,et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. , 2020, Journal of hepatology.
[8] K. Chayama,et al. Discordant pathological diagnosis of non‐alcoholic fatty liver disease: A prospective multicenter study , 2019, JGH open : an open access journal of gastroenterology and hepatology.
[9] Z. Goodman,et al. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials , 2019, Hepatology.
[10] Robert P. Myers,et al. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials , 2019, Hepatology.
[11] D. Thorburn,et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. , 2019, Journal of hepatology.
[12] Rohit Loomba,et al. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.
[13] R. Knight,et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease , 2019, Nature Communications.
[14] G. Shulman,et al. Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. , 2018, Cell metabolism.
[15] Michael Charlton,et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.
[16] V. Wong,et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.
[17] Zhen Wang,et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[18] T. Saibara,et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , 2015, Journal of Gastroenterology.
[19] P. Bedossa. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease , 2014, Hepatology.
[20] Rohit Loomba,et al. The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.
[21] T. Saibara,et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population , 2011, BMC Gastroenterology.
[22] B. Neuschwander‐Tetri,et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease , 2010, Hepatology.
[23] Chunhong Bai,et al. Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[24] I. Guha,et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers , 2007, Hepatology.
[25] T. Therneau,et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.
[26] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[27] D. Schuppan,et al. Serum markers detect the presence of liver fibrosis: a cohort study. , 2004, Gastroenterology.
[28] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.
[29] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[30] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.